BioPharmaceutical Business Intelligence

  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information
  • Drug patents in 130+ countries
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Federal Trade Commission
Novartis
Fish and Richardson
Mallinckrodt
Medtronic
US Army
Teva
Julphar
Fuji
Farmers Insurance

Generated: January 17, 2018

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 050710

« Back to Dashboard

NDA 050710 describes ZITHROMAX, which is a drug marketed by Pfizer and is included in seven NDAs. It is available from fourteen suppliers. There is one patent protecting this drug and one Paragraph IV challenge. Additional details are available on the ZITHROMAX profile page.

The generic ingredient in ZITHROMAX is azithromycin. There are thirty-two drug master file entries for this compound. Fifty-seven suppliers are listed for this compound. Additional details are available on the azithromycin profile page.
Summary for 050710
Tradename:ZITHROMAX
Applicant:Pfizer
Ingredient:azithromycin
Patents:1
Therapeutic Class:Antibacterials
Formulation / Manufacturing:see details
Pharmacology for NDA: 050710
Ingredient-typeMacrolides
Medical Subject Heading (MeSH) Categories for 050710
Suppliers and Packaging for NDA: 050710
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
ZITHROMAX azithromycin FOR SUSPENSION;ORAL 050710 NDA Pfizer Laboratories Div Pfizer Inc 0069-3110 0069-3110-19 1 BOTTLE in 1 CARTON (0069-3110-19) > 15 mL in 1 BOTTLE
ZITHROMAX azithromycin FOR SUSPENSION;ORAL 050710 NDA Pfizer Laboratories Div Pfizer Inc 0069-3120 0069-3120-19 1 BOTTLE in 1 CARTON (0069-3120-19) > 15 mL in 1 BOTTLE

Profile for product number 001

Active Rx/OTC/Discontinued:RXDosage:FOR SUSPENSION;ORALStrengthEQ 100MG BASE/5ML
Approval Date:Oct 19, 1995TE:ABRLD:Yes
Patent:➤ SubscribePatent Expiration:Jul 31, 2018Product Flag?Substance Flag?YDelist Request?

Profile for product number 002

Active Rx/OTC/Discontinued:RXDosage:FOR SUSPENSION;ORALStrengthEQ 200MG BASE/5ML
Approval Date:Oct 19, 1995TE:ABRLD:Yes
Patent:➤ SubscribePatent Expiration:Jul 31, 2018Product Flag?Substance Flag?YDelist Request?

Complete Access Available with Subscription

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Cantor Fitzgerald
US Army
Express Scripts
Dow
UBS
AstraZeneca
Merck
Federal Trade Commission
Teva

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot